Besides eradicating tumour cells with deficiencies for homologous recombination, PARP inhibitors can induce the activation of CAFs within the TME via NF-κB/CCL5 pathway. CCL5 blockade blunts the reprogramming of CAFs conditioned by PARP inhibitors and potentiates PARP inhibitors.
Chimeric antigen receptor (CAR)-T cell therapy is a new treatment option for certain cancers whose use in clinical practice presents novel challenges and opportunities. Here we highlight a review outlining some limitations and potential strategies to overcome the limitations of CAR-T cell therapy.
Cingöz et al. Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization. Oncogene, 2021.
You can consent to the use of such technologies by closing this notice.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activites described below. To learn more about how these trackers help us